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Background
CD4+ T cells are critical mediators of anti-tumor immu-
nity and orchestrate a broad range of immune responses
against cancer. Previous studies from our lab and others
have demonstrated that, adoptive transfer of tumor speci-
fic CD4+ T cells to lymphopenic hosts led to eradication
of established tumors in mice models. Accumulating evi-
dence from preclinical and clinical studies also suggest
that CD4+ T cells in combination with chemotherapy can
control tumor progression and recurrence. However, the
molecular and cellular mechanisms by which tumor reac-
tive CD4+ T cells eliminate a wide variety of tumors are
not completely understood.
Methods
In this project, we set out to study the mechanisms
underlying the therapeutic effect of chemo-immunother-
apy in the form of cyclophosphamide (CTX) and tumor
specific CD4+ T cells. Recent studies have revealed that
combined effect of Th-1 cytokines, IFN-g and TNF,
drive both murine and human cancer cells in to senes-
cence. In the present study we wanted to examine the
specific roles of IFN-g and TNF-a in the setting of che-
moimmunotherapy and the contribution of other
immune cells in the tumor microenvironment to tumor
rejection beside the donor CD4+ T cells.
Results
In a mouse model of colorectal cancer, we found that
host-derived interferon gamma (IFN-g) and expression of
IFN-gR are critical components of CD4+T cell-mediated
tumor rejection, whereas depletion of NK cells and
macrophages separately did not compromise the
therapeutic effect of the CTX and CD4+T cells regimen.
In addition, IFN-g appeared to drive tumor senescence
and apoptosis in vivo, leading to a curative outcome.
Furthermore, we analyzed the global metabolic profiling
of tumor tissues at different time points before and after
chemoimmunotherapy.
Conclusions
Our data suggests that CD4+T cells reprogram the
metabolic profiling in tumor, tipping the balance
towards progressive tumor regression. These findings
may provide new insights into mechanisms of tumor
rejection by CD4+ T cells, and may help develop more
effective anti-tumor strategies based on a rational combi-
nation of chemotherapy and anti-tumor CD4+ T cells.
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